PentaHibeBase

Objectives: to demonstrate that DMSO can be replaced with 16% PentaHibe Base as a safer cryoprotectant for the cryopreservation of peripheral blood stem cells.

Results: the recovery of viable CD34+ cells using PentaHibe Base is comparable to DMSO.2

Note: The recovery of CD34+ cells from apheresis samples after thawing is expressed as the percentage of the number of CD34+ cells before cryopreservation. Each data point represents duplicate measurements for each donor.

Objectives: colony-forming cell (CFC) assays were set up to investigate whether HPCs in cryopreserved HPC(A) samples retained their hematopoietic potential and were able to produce cells of the myeloid and erythroid lineages.

Samples cryopreserved in either 10% DMSO or 16% PentaHibe Base contained viable HPCs with the potential to produce colonies of the CFU-E and BFU-E, CFU-G, CFU-M, CFU-GM, and CFU-GEMM lineages.

Results: HPC(A) samples cryopreserved in either PentaHibe Base or DMSO show comparable colony-forming potential.2

Objectives: to measure hematopoietic engraftment of human CD45+ cells in 8-week peripheral blood samples from immunodeficient laboratory mice.

Engraftment was evaluated by flow cytometry, which was calculated as the frequency of human CD45+ cells in peripheral blood at 8 weeks post transplantation.

Results: Engraftment levels were comparable when using either PentaHibe Base or 10% DMSO at 8 weeks. No significant differences in the frequencies of human CD45+ cells in the samples cryopreserved in PentaHibe Base or DMSO.1

Objectives: to measure hematopoietic engraftment of human CD45+ cells in 16-week bone barrow samples from immunodeficient laboratory mice.

Engraftment was evaluated by flow cytometry, which was calculated as the frequency of human CD45+ cells in bone marrow at 16 weeks post transplantation.

Results: Engraftment levels were comparable when using either PentaHibe Base or 10% DMSO at 16 weeks. No significant differences in the frequencies of human CD45+ cells in the samples cryopreserved in PentaHibe Base or DMSO.1

Objectives: to evaluate the viability and recovery of T cells after cryopreservation with RPMI-1640 media supplemented with 10% PentaHibe Base, 2% DMSO and 4% human albumin.
T cells were isolated from buffy coats from healthy donors.

Results: T cells cryopreserved with 10% PentaHibe Base in a custom-made formulation demonstrate good viability and recovery after thaw.3

Objectives: to compare and evaluate the viability and recovery of T cells after cryopreservation with a self-made 10% DMSO formulation, a commercial product with 10% DMSO, or a custom-made formulation containing 10% Pentahibe® Base, 1% DMSO and 4% human albumin.

Results: T cells cryopreserved with a custom-made formulation with 10% Pentahibe® Base and only 1% DMSO show similar viability and recovery to self-made and commercial formulations with 10% DMSO.4

Objectives: to evaluate the recovery and proliferation of T cells cryopreserved in a low-DMSO, fully animal-origin-free formulation (10% PentaHibe Base + 4% recombinant HSA [Optibumin® 25] + 2% DMSO), and to compare its performance with commercial animal-origin-free products containing 10%, 5%, or 2% DMSO.

Results: T cells cryopreserved with PentaHibe Base + Optibumin 25 showed comparable or superior post-thaw viability and expansion across donors relative to commercial products with 10% and 5% DMSO, while significantly outperforming the product with 2% DMSO, despite containing the same reduced DMSO level (2%). The formulation maintained strong T cell proliferation at 72h, supporting its use as a fully defined, animal-origin-free cryopreservation strategy.8